NICOCCINO’S NICOTINE PATENT NOW ACCEPTED IN NEW ZEALAND
The New Zealand’s Intellectual Property Office has notified Nicoccino AB with the acceptance of the Company’s own nicotine patent application. The approval was published on September 30thand a three months Opposition Period will follow where interest party can file an opposition. If no opposition is filed, the patent letter will be sealed and granted.
New Zealand is the second marked to approve the patent since Singapore’s approval in March earlier this year.
As the nicotine patent is based on the plattform patent that Nicoccino AB uses through licensing, the protection of the product is extended until 2033.
”Obviously, it is very satisfying to see more markets taking after Singapore to approve the nicotine patent application. This is a further step in enhancing the patent protection and increases the confidence of our shareholders and international stakeholders that we are in dialogue with.” says Anders Ulfhielm, CEO at Nicoccino Holding AB.
The platform patent is so far approved in Sweden, US, China, Russia, Japan, Austria, New Zeeland, South Africa, Israel, South Korea and Canada. Nicoccino has submitted the application for nicotine patent in additional fourteen countries and in the EU.
Nicoccino has developed an innovative and patented nicotine product that after completion of a clinical study will be classified as a medicine for smoking cessation (Nicotine Replacement Therapy – NRT). Sales to consumers will be managed indirectly through a license model with international partners.
Nicoccino`s head quarter is located in Täby outside of Stockholm. The company’s share has been listed on Nasdaq First North since June 2014 and can be found under the abbreviation NICO.
Remium Nordic AB is Nicoccino Holding’s Certified Adviser.
This information is information that Nicoccino Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 08:00 CET on 3rd Oct. 2016. This message has been communicated in Swedish and English. If differences between the versions exist, the Swedish version is pertained.
Anders Ulfhielm, CEO, Nicoccino Holding AB
+4670-594 7618 email@example.com
Nicoccino has developed a patented, innovative and discrete strip that through its unique delivery method instantly provides the user with nicotine without the detrimental side effects of smoking. The product is designed to offer smokers an attractive alternative when they want to quit smoking. After a pharmaceutical approval, the product will be sold as a smoking cessation drug (Nicotine Replacement Therapy – NRT).
Some cookies are required to give you access to the website, while others are used to upgrade your user experience and are voluntary to accept. Choose below if you agree to us processing cookies to enable and analyze the provision of functionalities by third parties (eg social media plugins) and improve your user experience by analyzing your use of the website.